eISSN: 1897-4317
ISSN: 1895-5770
Gastroenterology Review/Przegląd Gastroenterologiczny
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
1/2009
vol. 4
 
Share:
Share:
more
 
 
abstract:
Review paper

Treatment of chronic hepatitis B and drug resistance

Khalil Nazzal

Przegląd Gastroenterologiczny 2009; 4 (1): 7–11
Online publish date: 2009/03/16
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
For more than ten years standard therapy of chronic hepatitis B was limited to interferon-a and lamivudine. Interferon-a is known to have several adverse effects, while the use of lamivudine is associated with HBV (hepatitis B virus) mutations. New nucleoside/nucleotide analogues have been registered during the last few years. New antiviral agents with different mechanisms of action than that of nucleotide/nucleoside analogues should be used in the future to achieve the optimal goal of therapy: the total eradication of HBV infection.
keywords:

hepatitis B, nucleoside analogue, therapy, mutation, drug resistance

Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe